BACKGROUND: SELECT was the first global randomised controlled trial of selexipag with standard of care in patients with inoperable or persistent/recurrent chronic thromboembolic pulmonary hypertension. METHODS: SELECT was a multicentre, randomised, double-blind, placebo-controlled, parallel-group, group-sequential, phase 3 study (NCT03689244). Adults aged
- Kim, N. H.
- Channick, R.
- Delcroix, M.
- Madani, M.
- Pepke-Zaba, J.
- Borissoff, J. I.
- Easton, V.
- Gesang, S.
- Richard, D.
- Ghofrani, H. A.
